Randomized Controlled Trial
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Jun 15, 2022; 14(6): 1187-1198
Published online Jun 15, 2022. doi: 10.4251/wjgo.v14.i6.1187
Table 4 QLQ-CR38 scores of four groups before and after treatment (mean ± SD, min)
Group dimension
Group A
Group B
Group C
Group D
Baseline
12 wk
Baseline
12 wk
Baseline
12 wk
Baseline
12 wk
Functional dimension
Body image43.17 ± 16.4549.45 ± 12.25a41.32 ± 16.7750.46 ± 13.24b43.43 ± 17.1653.43 ± 15.05b42.48 ± 13.3879.78 ± 13.75b,e
Future expectation42.48 ± 13.2747.48 ± 11.8342.14 ± 14.4261.93 ± 15.58b,e43.64 ± 16.6562.75 ± 15.16b,e41.52 ± 15.6080.48 ± 10.68b,e
Sexual function23.45 ± 9.4930.45 ± 12.65b24.32 ± 8.3535.82 ± 12.42b22.64 ± 8.1336.46 ± 11.55b23.48 ± 9.3743.33 ± 13.38b,e
Sexual satisfaction38.52 ± 12.4243.30 ± 13.72a39.07 ± 11.2652.29 ± 11.92b,e40.07 ± 14.2753.71 ± 12.60b,e39.33 ± 13.2165.07 ± 14.07b,e
Symptom dimension
Urination problem45.28 ± 14.1442.38 ± 12.0544.86 ± 13.6435.29 ± 10.73b,d46.18 ± 12.1635.29 ± 12.39b,d44.56 ± 13.6023.44 ± 7.80b,e
Gastrointestinal symptoms37.34 ± 13.5535.45 ± 11.0638.46 ± 16.6528.50 ± 12.71b,d37.21 ± 15.3527.54 ± 10.85b,e38.44 ± 14.1917.63 ± 9.37b,e
Adverse reactions of chemotherapy14.34 ± 4.5329.28 ± 6.64b15.54 ± 7.0926.18 ± 7.49b15.46 ± 5.9025.96 ± 5.98b15.26 ± 5.1618.41 ± 4.91a,e
Defecation problem23.52 ± 9.7035.38 ± 8.67b24.18 ± 8.6430.18 ± 7.83b,d23.43 ± 7.3629.82 ± 9.29b,d24.56 ± 8.1626.33 ± 6.52e
Issue related to stoma50.45 ± 11.3044.52 ± 11.23a50.50 ± 10.9036.29 ± 9.08b,e49.54 ± 12.2338.18 ± 6.91b,e49.33 ± 11.6824.74 ± 6.76b,e
Male sexual problems60.83 ± 14.9051.07 ± 13.44b62.11 ± 11.2545.71 ± 12.18b60.93 ± 14.0343.64 ± 10.73b,d61.56 ± 13.2742.63 ± 11.08b,e
Female sexual problems26.72 ± 8.6923.38 ± 5.80b27.43 ± 7.7121.68 ± 5.83b27.86 ± 6.9020.36 ± 5.70b27.52 ± 8.1018.30 ± 5.77b,e
Body mass54.48 ± 14.1949.41 ± 11.97a55.32 ± 13.6541.11 ± 9.87b,e55.18 ± 11.4442.68 ± 11.67b,d55.11 ± 16.5434.74 ± 9.65b,e